<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396537</url>
  </required_header>
  <id_info>
    <org_study_id>F130917005</org_study_id>
    <nct_id>NCT02396537</nct_id>
  </id_info>
  <brief_title>Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration</brief_title>
  <official_title>Efficacy of Topical Lidocaine to Decrease Discomfort With Intranasal Midazolam Administration: A Double-blind, Randomized, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to establish whether premedication with topical lidocaine would
      reduce the pain associated with IN midazolam administration in children. The study was
      designed to be a double-blinded, randomized, placebo-controlled trial performed in an urban,
      academic pediatric emergency department.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a double-blinded, randomized, placebo-controlled trial performed in an urban,
      academic pediatric emergency department with an annual census of 67,000 patients. Children
      6-12 years old for whom IN midazolam was ordered were eligible for enrollment. Patients were
      randomly assigned an identical intranasal medication (4% Lidocaine or 0.9% saline). Patients
      were administered the study drug followed by IN midazolam. Patients then assigned a pain
      score for midazolam administration using the Wong-Baker FACES Pain Rating scale. The primary
      endpoint of pain score was analyzed with a two-tailed Mann-Whitney U test, with P &lt; 0.05
      considered statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Discomfort With Intranasal Midazolam Administration</measure>
    <time_frame>immediately after administration of intranasal midazolam</time_frame>
    <description>subject self-reports pain with intranasal midazolam utilizing the Wong-Baker FACES Pain Scale. This scale is a well-established ordinal pain scale for pediatric patients. It is one score (no subscales), with a minimum score of 0 (signifying &quot;No Hurt&quot;) and a maximum score of 10 (&quot;Hurts Worst&quot;). Values between include 2 (&quot;Hurts Little Bit&quot;), 4 (&quot;Hurts Little More&quot;), 6 (&quot;Hurts Even More&quot;), and 8 (&quot;Hurts Whole Lot.&quot;). Children indicate one value/answer. Thus, a higher score indicates a worse outcome (more pain).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Intranasal Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient to receive 4% lidocaine intranasally prior to midazolam</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal 0.9% saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patient to receive 0.9% Saline intranasally prior to midazolam</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Administered intranasally prior to Midazolam administration.</description>
    <arm_group_label>Intranasal Lidocaine</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.</description>
    <arm_group_label>Intranasal Lidocaine</arm_group_label>
    <arm_group_label>Intranasal 0.9% saline</arm_group_label>
    <other_name>Versed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Saline</intervention_name>
    <description>Administered intranasally prior to Midazolam administration.</description>
    <arm_group_label>Intranasal 0.9% saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ages 6-12

          -  Previously healthy

          -  Attending physician concludes that the patient would benefit from administration of an
             anxiolysis medication prior to a minor procedure

        Exclusion Criteria:

          -  Moderate to severe asthma or other chronic lung disease

          -  Co-morbid conditions including cerebral palsy, developmental delay, or other chronic
             illness deemed by the Attending physician to be unsafe to receive anxiolysis with
             Versed.

          -  Any child presenting with a life-threatening condition.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UAB Department of Pediatrics</affiliation>
  </overall_official>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 11, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <results_first_submitted>August 9, 2016</results_first_submitted>
  <results_first_submitted_qc>January 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">February 23, 2017</results_first_posted>
  <last_update_submitted>January 4, 2017</last_update_submitted>
  <last_update_submitted_qc>January 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Christopher Pruitt</investigator_full_name>
    <investigator_title>Pediatric Emergency Medicine Faculty Advisor</investigator_title>
  </responsible_party>
  <keyword>Children</keyword>
  <keyword>Midazolam</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Intranasal</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intranasal Lidocaine</title>
          <description>Patient to receive 4% lidocaine intranasally prior to midazolam
Lidocaine: Administered intranasally prior to Midazolam administration.
Midazolam: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.</description>
        </group>
        <group group_id="P2">
          <title>Intranasal 0.9% Saline</title>
          <description>Patient to receive 0.9% Saline intranasally prior to midazolam
Midazolam: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
0.9% Saline: Administered intranasally prior to Midazolam administration.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="40"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intranasal Lidocaine</title>
          <description>Patient to receive 4% lidocaine intranasally prior to midazolam
Lidocaine: Administered intranasally prior to Midazolam administration.
Midazolam: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.</description>
        </group>
        <group group_id="B2">
          <title>Intranasal 0.9% Saline</title>
          <description>Patient to receive 0.9% Saline intranasally prior to midazolam
Midazolam: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
0.9% Saline: Administered intranasally prior to Midazolam administration.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="40"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="B2" value="9" lower_limit="7" upper_limit="10"/>
                    <measurement group_id="B3" value="8" lower_limit="7" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Discomfort With Intranasal Midazolam Administration</title>
        <description>subject self-reports pain with intranasal midazolam utilizing the Wong-Baker FACES Pain Scale. This scale is a well-established ordinal pain scale for pediatric patients. It is one score (no subscales), with a minimum score of 0 (signifying &quot;No Hurt&quot;) and a maximum score of 10 (&quot;Hurts Worst&quot;). Values between include 2 (&quot;Hurts Little Bit&quot;), 4 (&quot;Hurts Little More&quot;), 6 (&quot;Hurts Even More&quot;), and 8 (&quot;Hurts Whole Lot.&quot;). Children indicate one value/answer. Thus, a higher score indicates a worse outcome (more pain).</description>
        <time_frame>immediately after administration of intranasal midazolam</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intranasal Lidocaine</title>
            <description>Subjects were administered 4% lidocaine solution, 0.5 ml in each naris, 5 minutes prior to intranasal midazolam (intervention group).</description>
          </group>
          <group group_id="O2">
            <title>Intranasal 0.9% Saline</title>
            <description>Subjects were administered 0.9% saline, 0.5 ml in each naris, 5 minutes prior to intranasal midazolam (placebo group).</description>
          </group>
        </group_list>
        <measure>
          <title>Discomfort With Intranasal Midazolam Administration</title>
          <description>subject self-reports pain with intranasal midazolam utilizing the Wong-Baker FACES Pain Scale. This scale is a well-established ordinal pain scale for pediatric patients. It is one score (no subscales), with a minimum score of 0 (signifying &quot;No Hurt&quot;) and a maximum score of 10 (&quot;Hurts Worst&quot;). Values between include 2 (&quot;Hurts Little Bit&quot;), 4 (&quot;Hurts Little More&quot;), 6 (&quot;Hurts Even More&quot;), and 8 (&quot;Hurts Whole Lot.&quot;). Children indicate one value/answer. Thus, a higher score indicates a worse outcome (more pain).</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="6"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>duration of study (8 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intranasal Lidocaine</title>
          <description>Patient to receive 4% lidocaine intranasally prior to midazolam
Lidocaine: Administered intranasally prior to Midazolam administration.
Midazolam: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.</description>
        </group>
        <group group_id="E2">
          <title>Intranasal 0.9% Saline</title>
          <description>Patient to receive 0.9% Saline intranasally prior to midazolam
Midazolam: Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
0.9% Saline: Administered intranasally prior to Midazolam administration.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="37"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christopher Pruitt</name_or_title>
      <organization>University of Alabama at Birmingham</organization>
      <phone>2056389587</phone>
      <email>cpruitt@peds.uab.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

